Your session is about to expire
← Back to Search
SL-401 for Chronic Myelomonocytic Leukemia
Study Summary
This trial is testing a new drug, tagraxofusp, to see if it is safe and effective in treating patients with either chronic myelomonocytic leukemia or myelofibrosis who have not responded to other treatments.
- Chronic Myelomonocytic Leukemia
- Myelofibrosis
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Could you provide an overview of the additional experiments conducted with SL-401?
"SL-401 was first researched at University of California, Los Angeles in 2014. Since then two clinical trials have concluded and presently there are 7 active ones that take place predominantly in Duarte, Kansas."
What risks have been identified with the administration of SL-401?
"Considering the Phase 2 status of SL-401, there is evidence to suggest that its safety can be quantified as a two on our team's scale. However, efficacy data is still required for further assessment."
How many medical sites are hosting this clinical experiment?
"At the moment, 10 different medical sites are recruiting for this trial. Locations include Duarte, Westwood and Louisville among other places. To minimise travel expenses associated with participation in the study it is best to opt for a clinic nearby."
Is this research endeavor actively seeking participants?
"Clinicaltrials.gov shows that the trial, initially posted on December 1st 2014 and recently revised in April of 2022, is still recruiting participants."
Share this study with friends
Copy Link
Messenger